開拓藥業-B(09939.HK)與ETANA就普克魯胺治療新型肺炎在印尼商業化達成合作
開拓藥業-B(09939.HK)公布,於今日(25日),公司與PT Etana Biotechnologies Indonesia(一家專注於東南亞市場的印尼生物技術公司,主要業務為腫瘤領域生物製劑的生產及商業化)就普克魯胺治療COVID-19在印尼的商業化訂立許可協議。
根據許可協議,公司將從Etana收取首付款及里程碑付款,此外還將獲得普克魯胺在印尼上市銷售相關的經濟利益,該交易符合行業慣例。
公司指,作為開拓藥業開發的新一代雄激素受體拮抗劑,普克魯胺目前正在美國、南美洲(包括巴西)、歐洲及亞洲等多個國家及地區,進行兩項用於治療COVID-19輕中症患者的註冊性III期全球多中心臨床試驗,及一項用於治療COVID-19住院患者的註冊性III期全球多中心臨床試驗。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.